Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Fresenius Medical Care AG and Co. KGaA (NYSE: FMS - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $23.13 and traded as high as $23.92. Fresenius Medical Care AG and Co. KGaA shares last traded at $23.43,
These stocks have economic moats and look attractive today.
Fresenius Medical Care AG and Co. KGaA (NYSE: FMS) reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half. Chief Executive Officer Helen Giza said the company's operating-income growth accelerated
FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
Silicon Motion Technology Corporation (NasdaqGS: SIMO) (âSilicon Motionâ), a global leader in designing and marketing NAND flash controllers for solid-state
Fresenius Medical Care AG and Co. KGaA (NYSE: FMS - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $23.13 and traded as high as $23.92. Fresenius Medical Care AG and Co. KGaA shares last traded at $23.43,
These stocks have economic moats and look attractive today.
Fresenius Medical Care AG and Co. KGaA (NYSE: FMS) reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half. Chief Executive Officer Helen Giza said the company's operating-income growth accelerated
FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
Silicon Motion Technology Corporation (NasdaqGS: SIMO) (âSilicon Motionâ), a global leader in designing and marketing NAND flash controllers for solid-state
TAIPEI, Taiwan--(BUSINESS WIRE)-- #AIStorage--Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion”), a global leader in designing and marketing NAND flash controllers for solid-state storage devices, today announced it will showcase its latest storage innovations for AI Factory, Edge AI, and Physical AI applications at Future of Memory and Storage (FMS) 2026, taking place August 4 to 6 in Santa Clara, California, at Booth #315. As AI evolves beyond large language model training toward Ag.
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half.
Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.
TOKYO--(BUSINESS WIRE)--Kioxia will showcase the innovations driving the performance, scalability, and efficiency required for next-generation AI infrastructure at FMS 2026.
Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to focus on a fresh disappointment in U.S. patient volumes and the management's decision to merely confirm, not raise, the full-year guidance.
Fresenius Medical Care on Monday reported second-quarter operating income well ahead of market expectations and reaffirmed its full-year outlook, as its cost-cutting programme and favourable U.S. reimbursement rates offset a deepening decline in patient treatment volumes.
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $MRVL #AI--Marvell Technology, Inc. (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, today announced it will showcase its comprehensive portfolio of AI memory and storage solutions at FMS 2026 from August 4 to 6 at the Santa Clara Convention Center and Hyatt Regency in Santa Clara, California. As agentic AI inference scales, memory capacity, bandwidth and connectivity are becoming as critical as compute. Larger models, longer context windows an.
TAIPEI, Taiwan--(BUSINESS WIRE)-- #DataCenterStorage--Silicon Motion Technology Corporation (NasdaqGS: SIMO) (“Silicon Motion”), a global leader in designing and marketing NAND flash controllers for solid-state storage devices, today announced it will showcase its latest storage innovations for AI Factory, Edge AI, and Physical AI applications at Future of Memory and Storage (FMS) 2026, taking place August 4 to 6 in Santa Clara, California, at Booth #315. As AI evolves beyond large language model training toward Ag.
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.
Ryder System, Inc. (NYSE: R) reported results for the three months ended June 30 as follows: This press release features multimedia. View the full release her
Fresenius Medical Care has significant growth potential, driven by catalysts including new product rollouts and potentially improved patient outcomes. FMS's Care Delivery segment shows solid underlying earnings growth, with potential upside if patient outcomes continue to improve. Key risks include the expiration of €80M/quarter CMS incentive payments by the end of 2026 and possible stagnation in Care Enablement external sales.
FMS is a defensive dialysis services provider with stable and recurring demand and regulated pricing. Profitability is recovering as FME25+ cost savings flow through the business. The stock offers attractive shareholder returns through high free cash flow, dividends, and large buybacks.
FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce that it has filed the report on SEDAR+ for the upgraded mineral resource estimate ("MRE") on its 100%-owned Lac Tetepisca Project (the "Project") in Quebec. The Project lies within the Nitassinan (ancestral land) of the Pessamit Innu First Nation of Betsiamites, Quebec.
Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and advanced graphite materials for battery, defence, and industrial applications, is pleased to announce the completion of the Hydrogeological Assessment (the "Assessment" or the "Study") for its wholly-owned Lac Knife Graphite Project ("Lac Knife" or the "Project"), concluding a multi-year environmental program and completing the major technical work required to support the Company's Environmental and Social Impact Assessment ("ESIA") submission. Completed by Yves Leblanc, P.Geo.
FMS scales 5008X high-volume HDF and expands home dialysis, aiming for benefits later in 2026 and a bigger payoff in 2027+.
Fresenius Medical Care launches kinexus, a home dialysis platform integrating remote monitoring, prescription management and supply ordering for PD and HHD.
Global launch of a single, integrated digital platform connecting remote therapy monitoring and operational workflows for home dialysis programs Designed to simplify care processes for healthcare teams and their patients to support high-quality, personalized care for patients dialyzing at home Enables managing peritoneal dialysis and home hemodialysis therapies across Fresenius Medical Care's global home dialysis portfolio in one digital platform BAD HOMBURG, Germany, June 3, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the global launch of kinexus, a unified digital platform designed to support home dialysis programs and strengthen connected, patient-centered care. With kinexus, Fresenius Medical Care (FME) is advancing connected home dialysis care by bringing together digital modules supporting peritoneal dialysis (PD) and home hemodialysis (HHD) within a single, unified platform.
